about
Remote versus face-to-face check-ups for asthmaLong-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseEffects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoeaIndacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary diseaseThis Cochrane Review is closed: deciding what constitutes enough research and where next for pulmonary rehabilitation in COPDCombination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and childrenLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisHolding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthmaRegular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsIonisers for chronic asthmaLong-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary diseaseSafety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviewsAlexander technique for chronic asthmaVaccines for preventing influenza in people with asthmaInhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseAddition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthmaInhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary diseaseRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsTailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adultsCaffeine for asthmaCombination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and childrenCulture-specific programs for children and adults from minority groups who have asthmaFluticasone at different doses for chronic asthma in adults and childrenFluticasone versus placebo for chronic asthma in adults and childrenRegular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsCombination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and childrenTailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adultsCulture-specific programs for children and adults from minority groups who have asthmaVaccines for preventing influenza in people with asthmaCombined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary diseaseFluticasone versus beclomethasone or budesonide for chronic asthma in adults and childrenLong-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthmaContinuous positive airways pressure for obstructive sleep apnoea in adultsFluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and childrenTailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adultsIonisers for chronic asthmaHolding chambers versus nebulisers for beta-agonist treatment of acute asthmaHome telemonitoring and remote feedback between clinic visits for asthmaLong-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies
P50
Q24185891-CD954EDA-EA93-433C-A30D-2564DF08AEB5Q24186411-A2AD4914-9DBC-4D24-ADA6-09855C286E3EQ24186476-461D1F29-94FD-4441-9565-0C3CC13EBC9EQ24186652-3EAE160B-D443-48DB-B72B-CA2CC800BC94Q24187583-8392F7AB-566D-4BA5-9599-7AAA4DA2ED4CQ24197662-22033209-F219-4B86-82CE-8EC590FDD153Q24197853-899D884D-E9B3-4E51-892A-38F3A49D19FBQ24198076-02EA6549-B9CB-478C-B43A-3CBDA4D9FC22Q24199079-3601F8A5-4DC1-4F33-803D-9AE68ADF7F46Q24200323-C31460BD-B3A0-4A0A-AFA2-6B22FF64CBCFQ24200331-82DD5B2B-7CDD-4D4A-A5A6-A3B25FD65DC2Q24200620-19A1BB47-8E31-4CD5-BA89-FBD488A6B730Q24200673-EEAF7846-997C-4D1B-B67C-8AE31663160FQ24200871-0FD22DA1-E728-4A4C-963D-82AD202BDE42Q24234164-39E05125-0141-47BD-B1F4-003657C6815EQ24234499-BC9BA9F2-34E0-4306-8AF0-DF71772688BEQ24235496-1BB28699-6499-4DFA-AE92-079EE522CC32Q24236037-2105D4DC-C0AB-4F5B-8FD8-5970FC1B35F1Q24240282-573AF27C-3E7E-4C90-BD6F-9CEB25B43C15Q24240518-0B10E91D-40F3-43DD-A0AD-79C2FF098E92Q24240681-AEC0D43C-DBCD-4DDB-8585-F6FDD940665AQ24241025-9FBE9D8D-E8D1-4ED5-9FE5-5BC7E5EDF645Q24241105-85FB7E87-E35E-4FC9-AF96-E40E3DFE6E2AQ24241300-73C045F4-8696-4B57-AD57-A05A198E2658Q24241308-8E655E2C-E241-4FA0-B04D-2A1F7A9688D1Q24241453-A19899A8-1CE4-46CE-8A9A-7629AE40EBABQ24241556-39234BC9-DE0D-4E33-B277-32A6B9D507E4Q24242904-238A742F-5622-48A3-9551-0745FF935F13Q24243189-6C9C76F8-A77A-4432-91DC-E2486B824430Q24243265-5457131B-24C8-4E35-9C2B-CF109B079D30Q24243515-66588936-AEA0-477A-A055-ADD44CEB5873Q24243570-97163377-D3AF-404C-A7AE-48DBC05E9855Q24244152-39B700FA-9F2E-43E5-BBC6-93D09B43D51BQ24244929-959D5227-0F0B-44F9-8EF2-868A382297EDQ24245474-1916D689-6E32-4D59-9AD2-EA5984A317EAQ24245542-06CCDE2C-6701-41FF-8B1B-96B5417337D6Q24248663-69620A4B-0E63-423C-B9C3-B5A49B8AA920Q24248679-2A2CA339-F8A4-451D-A08F-C081972D6C74Q26470521-4B8D3FFF-8B2A-4031-85F8-4EB7821992CFQ27027449-E5DF3723-DC01-40F8-A0F4-BB0E0AF208D3
P50
description
researcher
@en
name
C Cates
@en
C Cates
@nl
type
label
C Cates
@en
C Cates
@nl
prefLabel
C Cates
@en
C Cates
@nl
P106
P31
P496
0000-0002-7056-9433